Ionis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of ($1.03), in-line with the analyst estimate of ($1.03). Revenue for the quarter came in at $144 million versus the consensus estimate of $132.91 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.